329 related articles for article (PubMed ID: 20104520)
1. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
[TBL] [Abstract][Full Text] [Related]
2. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.
Doyle SL; Donohoe CL; Finn SP; Howard JM; Lithander FE; Reynolds JV; Pidgeon GP; Lysaght J
Am J Gastroenterol; 2012 Feb; 107(2):196-204. PubMed ID: 22146489
[TBL] [Abstract][Full Text] [Related]
3. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
4. Absence or low IGF-1R-expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection.
De Bruijn K; Biermann K; Shapiro J; Dogan F; Spaander M; Janssen J; Wijnhoven B; Borsboom G; Hofland L; van Eijck C
J Surg Oncol; 2015 Jun; 111(8):1047-53. PubMed ID: 26082409
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor expression in thymic malignancies.
Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
8. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
[TBL] [Abstract][Full Text] [Related]
9. [Expression of IGF-1R in esophageal squamous cell carcinoma and the effect of its silencing by siRNA on the proliferation of esophageal cancer EC9706 cells in vitro].
Ma W; Li W; Fan QX; Wang LX; Wang RL; Lu SX
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):609-12. PubMed ID: 22325222
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
Zhang T; Shen H; Dong W; Qu X; Liu Q; Du J
Sci Rep; 2014 Oct; 4():6855. PubMed ID: 25358597
[TBL] [Abstract][Full Text] [Related]
11. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
13. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
Bhargava R; Beriwal S; McManus K; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
[TBL] [Abstract][Full Text] [Related]
15. Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma.
Rosato A; Pivetta M; Parenti A; Iaderosa GA; Zoso A; Milan G; Mandruzzato S; Del Bianco P; Ruol A; Zaninotto G; Zanovello P
Int J Cancer; 2006 Oct; 119(7):1717-22. PubMed ID: 16671090
[TBL] [Abstract][Full Text] [Related]
16. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
17. Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus.
Tihan T; Harmon JW; Wan X; Younes Z; Nass P; Duncan KL; Duncan MD
Anticancer Res; 2001; 21(4B):3107-14. PubMed ID: 11712819
[TBL] [Abstract][Full Text] [Related]
18. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
[TBL] [Abstract][Full Text] [Related]
19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
